Trial Profile

A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 27 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MOMA 313 (Primary) ; Olaparib
Indications Advanced breast cancer; Male breast cancer; Pancreatic cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors MOMA Therapeutics

Most Recent Events

23 Jul 2026 Status changed from active, no longer recruiting to recruiting.
17 Apr 2026 Status changed from recruiting to active, no longer recruiting.
17 Aug 2025 According to a MOMA Therapeutics media release, initial data readoutsn for MOMA-313 is expected in early-to- mid 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com